Nuvisan Pharma Holding GmbH

https://www.nuvisan.com

LinkedIn: https://de.linkedin.com/company/nuvisan

The NUVISAN group is a Contract Research and Development & Manufacturing Organization (CRO/CDMO) with six sites in Germany and France. NUVISAN offers unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain - from target to patient. Thanks to more than 40 years of experience and over 1,000 employees, NUVISAN supports its biotech startup, pharma, and venture capital partners to discover, develop, and bring the next generation medicines to market. NUVISAN ICB GmbH (Innovation Campus Berlin) was acquired by NUVISAN as a fully functional pharma R&D unit in 2020. NUVISAN ICB brings decades of successful drug discovery and development expertise in a broad indication spectrum including women’s and men’s health, oncology, and cardiovascular diseases. With all capabilities located under one roof in Berlin, NUVISAN ICB provides end-to-end solutions from target identification to pre-clinical candidates and IND, covering protein technologies, structural biology, high-throughput screening, computational and medicinal chemistry, pharmacology, translational research, drug metabolism & pharmacokinetics as well as toxicology. With a recent strategic investment from ALS Limited (ASX: ALQ), the NUVISAN group is today one of the fastest growing companies in the industry for the benefit of its partners and the patients they cure. *

	Start	2022-09-23 existent
	Group	Nuvisan (Group)
	Industry	contract research (drugs)
	Industry 2	small-molecule drug
	Person	Bruchmann, Dietrich (Nuvisan 2022 Managing Director of Nuvisan Pharma Holding GmbH)
	Person 2	Huisman, Arnoud (Nuvisan 202209 Managing Director of Nuvisan ICB + Chief Strategy Officer of Nuvisan Group)

	Region	Neu-Ulm
	Country	Germany
	Street	13 Wegenerstr.
	City	89231 Neu-Ulm
	Tel	+49-731-9840-0
		Address record changed: 2022-09-23

Basic data	Employees	n. a.

		* Document for »About Section«: Nuvisan ICB GmbH. (9/20/22). "Press Release: Nuvisan Receives US$ 9.6m Grant for a Multi-target Drug Discovery Program on Novel Non-hormonal Contraceptive Medicines". Berlin.

		Record changed: 2025-03-16

Picture Informa Connect BioProcess Intl Europe 2025 Hamburg Register 650x200px

More documents for Nuvisan (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)